Literature DB >> 21616681

Population pharmacokinetics of lidocaine administered during and after cardiac surgery.

Yung-Wei Hsu1, Jacques Somma, Mark F Newman, Joseph P Mathew.   

Abstract

OBJECTIVE: The objective of this study was to determine the pharmacokinetics of lidocaine in a 48-hour infusion in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB).
DESIGN: A retrospective substudy of a clinical trial assessing the efficacy of intravenous lidocaine for postoperative cognitive decline.
SETTING: A university hospital. PARTICIPANTS: Ninety-nine patients undergoing cardiac surgery with CPB.
INTERVENTIONS: After the induction of anesthesia, lidocaine was administered as a bolus of 1 mg/kg and followed by a continuous infusion at 4 mg/min for the 1st hour, 2 mg/min for the 2nd hour, and 1 mg/min for the next 46 hours.
MEASUREMENTS AND MAIN RESULTS: Blood samples were taken at baseline, the end of CPB, and 24 and 48 hours after CPB for the measurement of the plasma concentration of lidocaine. Lidocaine levels increased significantly over time despite a constant rate of infusion (p < 0.05). The pharmacokinetics of lidocaine was best described by a 2-compartment model, and body weight was found to be a significant factor for the volume of the central compartment and clearance. The final pharmacokinetic parameters were V(1)(L) = 0.0619*weight, V(2)(L) = 187, CL(1) (L/min) = 0.00419*weight, and CL(2) (L/min) = 8.92.
CONCLUSIONS: A 2-compartment pharmacokinetic model best describes the plasma concentrations of a 48-hour lidocaine infusion in patients undergoing cardiac surgery with CPB. The inclusion of body weight as a covariate on clearance and central compartment improves the model. Lidocaine infusions should be dosed by body weight and decreased after 24 hours to avoid potential toxicity in long-term infusions.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21616681      PMCID: PMC3203309          DOI: 10.1053/j.jvca.2011.03.008

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  19 in total

1.  Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans.

Authors:  P D Thomson; K L Melmon; J A Richardson; K Cohn; W Steinbrunn; R Cudihee; M Rowland
Journal:  Ann Intern Med       Date:  1973-04       Impact factor: 25.391

2.  Disposition kinetics of lidocaine in normal subjects.

Authors:  M Rowland; P D Thomson; A Guichard; K L Melmon
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

3.  Derivation and cross-validation of pharmacokinetic parameters for computer-controlled infusion of lidocaine in pain therapy.

Authors:  T W Schnider; R Gaeta; W Brose; C F Minto; K M Gregg; S L Shafer
Journal:  Anesthesiology       Date:  1996-05       Impact factor: 7.892

4.  Precursor-metabolite interaction in the metabolism of lidocaine.

Authors:  T Suzuki; S Fujita; R Kawai
Journal:  J Pharm Sci       Date:  1984-01       Impact factor: 3.534

Review 5.  The MEGX test: a tool for the real-time assessment of hepatic function.

Authors:  M Oellerich; V W Armstrong
Journal:  Ther Drug Monit       Date:  2001-04       Impact factor: 3.681

6.  Pharmacokinetic principles of lidocaine dosing in relation to disease state.

Authors:  E S Waller
Journal:  J Clin Pharmacol       Date:  1981-04       Impact factor: 3.126

Review 7.  Clinical pharmacokinetics of lignocaine.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

8.  The pharmacokinetics of lignocaine in humans during a computer-controlled infusion.

Authors:  J B Dyck; M S Wallace; J Q Lu; S S Rossi; T L Yaksh
Journal:  Eur J Pain       Date:  1997       Impact factor: 3.931

9.  Perioperative variability of binding of lidocaine, quinidine, and propranolol after cardiac operations.

Authors:  R F Davies; L M Dubé; N Mousseau; I McGilveray; D S Beanlands
Journal:  J Thorac Cardiovasc Surg       Date:  1988-10       Impact factor: 5.209

10.  Randomized, double-blinded, placebo controlled study of neuroprotection with lidocaine in cardiac surgery.

Authors:  Joseph P Mathew; G Burkhard Mackensen; Barbara Phillips-Bute; Hilary P Grocott; Donald D Glower; Daniel T Laskowitz; James A Blumenthal; Mark F Newman
Journal:  Stroke       Date:  2009-01-22       Impact factor: 7.914

View more
  15 in total

1.  Population pharmacokinetic model for tumescent lidocaine in women undergoing breast cancer surgery.

Authors:  Camille Riff; Aurélie Bourgoin; Amelie Marsot; Laurent Allanioux; Marc Leone; Olivier Blin; Romain Guilhaumou
Journal:  Eur J Clin Pharmacol       Date:  2018-06-16       Impact factor: 2.953

2.  Effect of intravenous lidocaine on the transcerebral inflammatory response during cardiac surgery: a randomized-controlled trial.

Authors:  Rebecca Y Klinger; Mary Cooter; Miles Berger; Mihai V Podgoreanu; Mark Stafford-Smith; Thomas L Ortel; Ian J Welsby; Jerrold H Levy; Henry M Rinder; Mark F Newman; Joseph P Mathew
Journal:  Can J Anaesth       Date:  2016-07-28       Impact factor: 5.063

Review 3.  Perioperative Use of Intravenous Lidocaine.

Authors:  Marc Beaussier; Alain Delbos; Axel Maurice-Szamburski; Claude Ecoffey; Luc Mercadal
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

4.  Intravenous Lidocaine Does Not Improve Neurologic Outcomes after Cardiac Surgery: A Randomized Controlled Trial.

Authors:  Rebecca Y Klinger; Mary Cooter; Tiffany Bisanar; Niccolò Terrando; Miles Berger; Mihai V Podgoreanu; Mark Stafford-Smith; Mark F Newman; Joseph P Mathew
Journal:  Anesthesiology       Date:  2019-06       Impact factor: 7.892

Review 5.  The Use of Intravenous Lidocaine in Perioperative Medicine: Anaesthetic, Analgesic and Immune-Modulatory Aspects.

Authors:  Ingrid Wing-Sum Lee; Stefan Schraag
Journal:  J Clin Med       Date:  2022-06-20       Impact factor: 4.964

6.  Utilization of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacoepidemiological Studies: A Systematic Review on Antiarrhythmic and Glucose-Lowering Medicines.

Authors:  Soroush Mohammadi Jouabadi; Mitra Nekouei Shahraki; Payam Peymani; Bruno H Stricker; Fariba Ahmadizar
Journal:  Front Pharmacol       Date:  2022-06-20       Impact factor: 5.988

7.  A method for evaluating drug penetration and absorption through isolated buccal mucosa with highly accuracy and reproducibility.

Authors:  Shuangqing Wang; Lei Liu; Saige Meng; Yuling Wang; Daofeng Liu; Zhonggao Gao; Along Zuo; Jianpeng Guo
Journal:  Drug Deliv Transl Res       Date:  2022-03-29       Impact factor: 5.671

Review 8.  Intravenous Lidocaine Infusion for the Management of Early Postoperative Pain: A Comprehensive Review of Controlled Trials.

Authors:  Robert Chu; Nelly Umukoro; Tiashi Greer; Jacob Roberts; Peju Adekoya; Charles A Odonkor; Jonathan M Hagedorn; Dare Olatoye; Ivan Urits; Mariam Salisu Orhurhu; Peter Umukoro; Omar Viswanath; Jamal Hasoon; Alan D Kaye; Vwaire Orhurhu
Journal:  Psychopharmacol Bull       Date:  2020-10-15

9.  Neuroprotective effects of intravenous lidocaine on early postoperative cognitive dysfunction in elderly patients following spine surgery.

Authors:  Kui Chen; Penghui Wei; Qiang Zheng; Jinfeng Zhou; Jianjun Li
Journal:  Med Sci Monit       Date:  2015-05-15

10.  Lidocaine versus ropivacaine for postoperative continuous paravertebral nerve blocks in patients undergoing laparoscopic bowel surgery: a randomized, controlled, double-blinded, pilot study.

Authors:  Daniela Ghisi; Andrea Fanelli; Julie Jouguelet-Lacoste; Luca La Colla; Anne-Sophie Auroux; Jacques E Chelly
Journal:  Local Reg Anesth       Date:  2015-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.